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Welcome and introductions
Moderators
• Michelle R. Guyton, 
Ph.D. (SPP)
• Cathy Moonshine, Ph.D. 
(SPP)
• Laura Dimmler, Ph.D.(c) 
(MHA)
• Shawna Rohner, RDH, 
BS  (DHS)
• Alicia Hendrix (DHS)
• Fraser Horn, OD, DAAO 
(OPT)
• Sean Roush, OTD, OTR/L 
(OT)
• Marianne Krupicka, RPh, 
PharmD (SOP)
• James Ferguson, PA-C 
(PA)
• John White, Ph.D., 
OTR./L (OT)
Today’s agenda
• Process description
• Background information on meth
• Case presentation
– 3 rounds of information
– Small group discussion
– Larger group summary
http://www.youtube.com/watch?v=L
65TR9IwlR8&feature=related
What is methamphetamine?
• Central nervous system stimulant
• Similar in structure to amphetamine, 
dopamine
• Limited medical use
• Methods of administration
• Manufactured in homes, “superlabs”
Methamphetamine
Meth lab
Scope of the problem--national
• Meth used increased 24% 1993-2003
• 2005 criminal justice and health care cost 
of meth—$23 billion
• Third most prevalent substance of abuse 
(behind alcohol and marijuana)
• Meth users predominantly White, 18-25, 
45% are female
•
Scope of the problem--Oregon
• Most widely abused drug currently
• More folks in OR seeking treatment for 
meth than any other state (per capita)
• Meth provided mostly by international 
superlabs, some clandestine labs
Methamphetamine Intoxication
• Development of a reversible syndrome due 
to recent ingestion of meth
• Significant behavioral or psychological 
changes due to meth’s effect on CNS 
during or shortly after use
Methamphetamine abuse
• Characterized by at least one of the 
following:
– Recurrent use resulting in work, school, or 
domestic failures
– Recurrent use in physically hazardous 
situations (driving, operating machinery while 
impaired)
– Recurrent amphetamine use related legal 
problems
– Continued use despite persistent social or 
inter-personal problems 20 amphetamine use
Methamphetamine Dependence
• 3 or more of the following
– Tolerance
– Withdrawal
– Taken in larger amounts over time than intended
– Unsuccessful attempts to quit
– A lot of time spent procuring or recovering from meth
– Social, occupational, or recreational activities reduced, 
given up for meth
– Meth use continues despite physiological or 
psychological problems likely due to use of it
Case presentation
Round 1 
• Patient has been referred to the CHP 
interdisciplinary clinic for assessment and 
treatment of methamphetamine use and 
associated problems
Case presentation
Round 1
• Discuss the following questions:
• How would you assess the patient?
• What are the patient’s clinical needs?
• How would you work with the other disciplines 
to prioritize the patient’s clinical needs?
• What treatment options are you considering?
• What are the financial concerns in her situation?
• What are the legal concerns?
“Meth mouth”
What are the physiological and psychological factors associated with “meth 
mouth?”
More “meth mouth”
Case presentation
Round 2
Discuss the following questions:
• How do you proceed with the new physical 
health data?
• How do you respond to Leanne’s request 
for medication?
Case presentation
Round 3
Consider the following questions:
• How do you respond to what Leanne has 
divulged?
• What are the legal implications of this new 
data?
• How does this new information impact your 
current treatment plan?
Summary points
• Financial and systemic constraints
– Lack of a “medical home” for care coordination
– Difficulty without comprehensive health care delivery 
system
• “Who is the client?” in releasing information
• Physical impact of meth use
• Working with survivors of sexual assault
• Medication management and self-medication
• Pathways to recovery
